Gossamer Bio’s (GOSS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Gossamer Bio’s Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.56) EPS, FY2027 earnings at ($0.04) EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.55 EPS.

Separately, Wedbush restated an “outperform” rating and set a $4.00 price objective on shares of Gossamer Bio in a report on Friday, March 14th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $9.20.

Gossamer Bio Stock Performance

GOSS stock opened at $1.35 on Tuesday. The business has a 50 day moving average of $1.16 and a 200-day moving average of $0.98. The firm has a market cap of $306.75 million, a PE ratio of -4.22 and a beta of 1.86. Gossamer Bio has a 12-month low of $0.50 and a 12-month high of $1.55. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $9.38 million during the quarter, compared to the consensus estimate of $7.02 million. As a group, sell-side analysts expect that Gossamer Bio will post -0.28 earnings per share for the current year.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio in the fourth quarter worth about $32,000. US Bancorp DE bought a new position in Gossamer Bio in the 3rd quarter worth approximately $39,000. Fullcircle Wealth LLC purchased a new position in Gossamer Bio in the 4th quarter valued at approximately $43,000. GSA Capital Partners LLP bought a new stake in Gossamer Bio during the 3rd quarter valued at $67,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Gossamer Bio during the fourth quarter worth $68,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.